Welcome to our dedicated page for PMGC Holdings SEC filings (Ticker: elab), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking PMGC Holdings’ evolution—from engineered probiotic obesity therapies to uranium-backed investments—means piecing together data scattered across dozens of SEC documents. Each quarter, disclosures blend biotech trial updates, medical aesthetics revenue, and capital deployment news, leaving investors asking how to locate all of it efficiently.
That’s where Stock Titan steps in. Whether you search “PMGC Holdings quarterly earnings report 10-Q filing” or “PMGC Holdings insider trading Form 4 transactions,” you land on a page that our AI has already translated into plain language. Real-time alerts surface “PMGC Holdings Form 4 insider transactions real-time,” while concise summaries answer the bigger question: “understanding PMGC Holdings SEC documents with AI.” From cash-burn trends to fresh 8-K deal announcements, complexity is distilled into clear takeaways.
- Annual insight – The “PMGC Holdings annual report 10-K simplified” section highlights pipeline milestones for Northstrive Biosciences and funding details for aesthetic R&D.
- Quarterly pulse – “PMGC Holdings earnings report filing analysis” compares segment revenue shifts and R&D spend without digging through tables.
- Event radar – “PMGC Holdings 8-K material events explained” flags new fire-prevention or energy investments the moment they post.
- Governance clarity – Our proxy tools decode “PMGC Holdings proxy statement executive compensation,” mapping pay to performance across subsidiaries.
- Insider moves – Instant alerts for “PMGC Holdings executive stock transactions Form 4” help monitor sentiment before catalytic data releases.
Every document—10-Ks, 10-Qs, S-3s, 8-Ks, Form 4s—feeds into Stock Titan’s AI-powered summaries so you can navigate “PMGC Holdings SEC filings explained simply” and act on insights faster than ever.
PMGC Holdings Inc. (ELAB) is registering under Form S-1 and discloses a diversified holding structure with subsidiaries including Northstrive Biosciences, PMGC Capital, Pacific Sun Packaging and AGA Precision Systems. Northstrive's lead asset, EL-22, is an engineered probiotic program aimed at preserving muscle during weight-loss treatment and the company cites preclinical signals such as increased anti-myostatin antibodies, reduced creatine kinase and improved motor function in mdx mice.
The filing details recent M&A: acquisitions of Pacific Sun Packaging and AGA Precision Systems, a binding term sheet with Modulant for animal-health licensing, multiple patent applications, an ATM sales agreement up to $100 million and corporate actions including reverse splits and an increase in authorized shares to 2.5 billion. Financials show operating losses and cash use that raise substantial doubt about the company's ability to continue as a going concern.
PMGC Holdings Inc. Schedule 13G/A reports that L1 Capital Global Opportunities Master Fund, Ltd. beneficially owns 165,580 shares of PMGC common stock, representing 6.53% of the 2,369,727 shares outstanding after an offering. The filing explains these shares arose from the Reporting Person exercising warrants on August 25, 2025 at an adjusted exercise price of $2.015 per share under a warrant inducement agreement and receiving new warrants exercisable at $1.89. The new warrants underlying an additional 165,580 shares are subject to a 4.99% ownership limitation and require shareholder approval. The amendment also notes prior larger holdings reported in October 2024 were sold before August 25, 2025.
PMGC Holdings Inc. (ELAB) filed an 8-K reporting arrangements related to warrant inducement transactions. The filing references a Form of New Warrant and a Form of Warrant Inducement Agreement as exhibits and includes an Inline XBRL cover page. The disclosure states a payment of $146,775.30, described as 7% of the aggregate proceeds from the warrant inducement transactions and to cover certain fees and expenses. The document is signed by Graydon Bensler, Chief Executive Officer. Other check-box items and certain contextual details are present in fragmentary form but no earnings, balance sheet figures, or transaction counterparties are provided.
PMGC Holdings, Inc. filed an 8-K reporting amendments to two consulting agreements with Northstrive Companies Inc. (Non-Executive Chairman) and GB Capital Ltd (Non-Employee CEO). The amendments establish a tiered Acquisition Award schedule tied to acquisition value: 5% for $0–$5,000,000; 6% for $5,000,001–$10,000,000; 7% for $10,000,001–$20,000,000; and 8% for acquisition value above $20,000,000.
The filing lists two amendment exhibits and an Inline XBRL cover page file. The document is signed by Graydon Bensler, who is identified as Chief Executive Officer, Chief Financial Officer and Director.
PMGC Holdings Inc. reported total assets of $9.38M and cash of $5.68M at June 30, 2025, up from $3.98M at year-end 2024. Equity increased to $9.05M from $6.66M, largely reflecting equity financings during the period and retrospective reverse stock splits reducing share counts. For the six months ended June 30, 2025 the Company recorded a net loss of $2.17M and used $2.69M of cash in operating activities, compared with a $2.81M loss and $3.10M cash used in the prior year period.
The company sold its skincare business (closed January 16, 2025) for consideration including $728,550 in buyer shares and recognized a $39,676 loss on the sale; it also recorded a $129,613 gain on termination of a license agreement. Investments at June 30, 2025 totaled $624,838 (realized loss on sales $371,494; unrealized gain $238,899). Management discloses substantial doubt about going concern and plans to raise financing or acquire cash-generating assets; subsequent to quarter end it completed acquisitions of Pacific Sun Packaging (consideration $1,148,000 plus earnout) and AGA Precision Systems ($650,000).
On 25 Jul 2025, PMGC Holdings Inc. (Nasdaq: ELAB) filed an 8-K disclosing a Secondment Agreement with GB Capital Ltd., a company wholly owned by CEO/CFO/director Graydon Bensler. GB Capital will second its employees to PMGC on an exclusive, as-needed basis; the individuals remain GB employees.
Compensation: PMGC will reimburse GB Capital monthly at hourly rates listed in Exhibit A plus pre-approved extraordinary expenses. GB Capital continues to pay salaries and benefits.
Control & Risk Allocation: PMGC assumes full responsibility for the employees’ actions while seconded. The pact includes typical confidentiality, indemnification and liability-limit clauses.
Termination: PMGC may end any employee’s secondment with 15 days’ notice (immediate for misconduct) and may terminate the entire agreement with 30 days’ notice; GB Capital requires 90 days. Either party can terminate on 10 days’ notice for uncured breach.
Governance Note: Because the counterparty is owned by the CEO, this is a related-party transaction; dollar amounts of anticipated reimbursements are not disclosed. No financial results, guidance changes or capital actions were reported. A press release dated 30 Jul 2025 is furnished as Exhibit 99.1.
FAQ
What is the current stock price of PMGC Holdings (elab)?
What is the market cap of PMGC Holdings (elab)?
